NCT04389710View on ClinicalTrials.gov

Convalescent Plasma for the Treatment of COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 15, 2020

Primary Completion Date

November 3, 2020

Study Completion Date

December 7, 2020

Conditions
COVID-19
Interventions
DRUG

Convalescent Plasma

One to two units (200-600 mL) of ABO compatible COVID-19 convalescent plasma

Trial Locations (1)

19107

Thomas Jefferson University Hospital, Philadelphia

All Listed Sponsors
lead

Thomas Jefferson University

OTHER

NCT04389710 - Convalescent Plasma for the Treatment of COVID-19 | Biotech Hunter | Biotech Hunter